Checkpoint inhibitor‐based salvage regimens prior to autologous stem cell transplant improve event‐free survival in relapsed/refractory classic Hodgkin lymphoma
American Journal of Hematology · 2023-03 · 98 (3) · 464-471
DOI: 10.1002/ajh.26827 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift American Journal of Hematology, online erschienen am 11.01.2023. Verfasst von Sanjal H Desai und 29 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Hodgkin Disease, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Clinical trials of novel salvage therapies have encouraging outcomes for relapsed/refractory transplant‐eligible classic Hodgkin lymphoma (R/R cHL) but comparison with conventional chemotherapy is lacking. Herein, we report the final analysis of a multicenter retrospective cohort of R/R cHL assessing outcomes by type of salvage therapy before autologous stem cell transplant (ASCT). R/R cHL patients who underwent ASCT at 14 institutions across the United States were included. Outcomes were compared among patients receiving conventional chemotherapy, brentuximab vedotin (BV) + chemotherapy, BV alone, and a checkpoint inhibitor (CPI)‐based regimens before ASCT. Study endpoints included event‐free survival (EFS), progression‐free survival (PFS), and overall survival (OS). All endpoints are defined from relapse. Of 936 patients, 728 received conventional chemotherapy, 73 received BV + chemotherapy, 70 received BV alone, and 65 received CPI‐based regimens prior to ASCT. When adjusted for time to relapse, pre‐ASCT response and use of BV maintenance, patients receiving CPI‐based regimens had superior 2‐year EFS compared to conventional chemotherapy, BV + chemotherapy, and BV alone (79.7, 49.6, 62.3, and 36.9%, respectively, p < .0001). Among 649 patients transplanted after 1 line of salvage therapy, CPI‐based regimens were associated with superior 2‐year PFS compared to conventional chemotherapy (98% vs. 68.8%, hazard ratio: 0.1, 95% confidence interval: 0.03–0.5, p < .0001). OS did not differ by pre‐ASCT salvage regimen. In this large multicenter retrospective study, CPI‐based regimens improved EFS and PFS compared to other salvage regimens independent of pre‐ASCT response. These data support earlier sequencing of CPI‐based regimens in R/R cHL in the pre‐ASCT setting.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
- Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, USA.
- Division of Oncology, Department of Medicine, Stanford University Medical Center, Stanford, California, USA.
- Department of Hematology and Medical Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA.
- Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA.
- O'Neal Comprehensive Cancer Center, University of Alabama, Birmingham, Alabama, USA.
ORCID-Profile: Sanjal H Desai, Kevin David, Veronika Bachanova, Gaurav Goyal, Nuttavut Sumransub, Harsh Shah, Stephen Ansell
Förderung
- NCI NIH HHS
Zitieren
APA
Desai, S. H., Spinner, M. A., David, K., Bachanova, V., Goyal, G., Kahl, B., Dorritie, K., Azzi, J., Kenkre, V. P., Arai, S., Chang, C., Fusco, B., Sumransub, N., Hatic, H., Saba, R., Ibrahim, U., Harris, E. I., Shah, H., Murphy, J., …, & Micallef, I. N. (2023). Checkpoint inhibitor‐based salvage regimens prior to autologous stem cell transplant improve event‐free survival in relapsed/refractory classic Hodgkin lymphoma. American Journal of Hematology, 98(3), 464-471. https://doi.org/10.1002/ajh.26827
Vancouver
Desai SH, Spinner MA, David K, Bachanova V, Goyal G, Kahl B, et al. Checkpoint inhibitor‐based salvage regimens prior to autologous stem cell transplant improve event‐free survival in relapsed/refractory classic Hodgkin lymphoma. American Journal of Hematology. 2023;98(3):464-471. doi:10.1002/ajh.26827
BibTeX
@article{Desai2023,
author = {Desai, Sanjal H and Spinner, Michael A and David, Kevin and Bachanova, Veronika and Goyal, Gaurav and Kahl, Brad and Dorritie, Kathleen and Azzi, Jacques and Kenkre, Vaishalee P and Arai, Sally and Chang, Cheryl and Fusco, Brendon and Sumransub, Nuttavut and Hatic, Haris and Saba, Raya and Ibrahim, Uroosa and Harris, Elyse I and Shah, Harsh and Murphy, Jacob and Ansell, Stephen and Jagadish, Deepa and Orellana-Noia, Victor and Diefenbach, Catherine and Iyenger, Siddharth and Rappazzo, K C and Mishra, Rahul and Choi, Yun and Nowakowski, Grzegorz S and Advani, Ranjana H and Micallef, Ivana N},
title = {Checkpoint inhibitor‐based salvage regimens prior to autologous stem cell transplant improve event‐free survival in relapsed/refractory classic Hodgkin lymphoma},
journal = {American Journal of Hematology},
year = {2023},
volume = {98},
number = {3},
pages = {464--471},
doi = {10.1002/ajh.26827}
}
EUVIMED